Sanara MedTech (SMTI) Piper Sandler 36th Annual Healthcare Conference summary

Company history and strategic evolution

• Acquired CellerateRX in 2018 to build a surgical business, later rebranding and investing $10 million in 2019.

• Uplisted to Nasdaq in 2020, strengthened Board with technical and industry expertise.

• Raised $32 million in 2021, reducing majority ownership to 41% without selling stock.

• Acquired Rochal Industries and other biologics companies to expand R&D and product portfolio.

• Entered joint venture with InfuSystem and licensed proprietary collagen peptides in 2024.

Product platforms and innovation

• Core platforms are CellerateRX (hydrolyzed collagen) and BIASURGE (antimicrobial surgical wash).

• CellerateRX offers fast-acting wound healing, with applications expanding beyond ortho and spine.

• BIASURGE is the first leave-in antimicrobial wash for surgery, targeting reduction of surgical site infections.

• Ongoing focus on expanding IP and developing specialty-specific products.

• Evidence-based outcomes drive product adoption, with studies showing significant infection reduction.

Market penetration and growth

• Products approved in over 4,000 hospitals, currently in 1,200+ across 34 states.

• Achieved $78 million trailing 12-month revenue, with 25% year-over-year growth.

• Strong sales team and distribution network support multi-product sales per case.

• Significant greenfield opportunity remains with 2,800+ untapped hospitals.

• Growth strategy includes both organic expansion and targeted acquisitions.